1. DENGUE VACCINE

3. Introduction

4. Main Areas at Risk for Dengue

5. Incidence of Dengue in Brazil

6. Incidence of Dengue in Mexico: 1990 to 2016

7. Suspected Cases of Dengue Disease in the Philippines: 2015 to 2016

8. Incidence of Dengue in Malaysia: 1995 to 2016

9. Dengue Deaths in Malaysia: 1995 to 2016

10. Dengue Infection

11. Secondary Infection and Risk for Severe Dengue

12. Immunopathogenesis of Severe Dengue in Secondary Infections

13. Dengue: Clinical Picture

14. Preventing Infection

15. Dynamics of Circulating Serotypes in Mexico

16. Strategies in Place for Vector Control: A Challenge Remains

17. Development of the Dengue Vaccine

18. Phase 3 Trials of CYD-TDV Vaccine: Efficacy

19. CYD-TDV Vaccine: Efficacy According Baseline Serologic Status, Age and Region

20. Reduction in Dengue in Patients Aged 9 to 16 Years During the Efficacy Phase

21. Philippine Dengue Vaccine School-Based Immunization Program

22. Reactogenicity of CYD-TDV Vaccine

23. Public Immunization Program Against Dengue in Brazil

24. Recombinant Live Attenuated Dengue Vaccine in Licensed and/or Late-Stage Clinical Trials

25. WHO Position: Countries That Should Consider Introducing Dengue Vaccine

26. CYD-TDV Vaccine Age Indications

27. Changing the Vaccine Paradigm

28. Estimated Impact of Dengue Vaccination

29. Real-World Survey of Attitudes Toward Dengue Vaccination in Malaysia

30. Key Points From the Philippines

31. Key Points From Mexico

32. Closing Remarks

33. Abbreviations